Treatment concerns for psychiatric symptoms in patients with COVID-19 with or without psychiatric disorders
Open Access
- 9 April 2020
- journal article
- editorial
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 217 (1), 351
- https://doi.org/10.1192/bjp.2020.84
Abstract
Many psychiatric patients have been infected with COVID-19, and patients with COVID-19 may develop psychiatric symptoms after treatment with antiviral drugs. Given the tolerability and minimal P450 interactions, antidepressants (i.e., citalopram, escitalopram etc.), antipsychotics (i.e., olanzapine) and valproate can be considered to be safe in combination with antiviral drugs.Keywords
This publication has 2 references indexed in Scilit:
- A novel coronavirus outbreak of global health concernThe Lancet, 2020
- The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugsExpert Review of Clinical Pharmacology, 2018